116 Advanced Solid Tumors Clinical Trials in New York, NY (2026)

Q: How do I join a clinical trial in New York?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you.

Recruiting Advanced Solid Tumors Studies in New York

NCT05390827Recruiting

Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol

The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this information to learn more about how physiologic d...

New York, NY3,692 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06963723Recruiting

Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer

The study aims to determine whether monthly remote digital financial hardship screening among adults with advanced/metastatic cancer, undergoing outpatient systemic therapy with non-curative intent, i...

New York, NYNA1,000 participantsAlliance Foundation Trials, LLC.

View Study Details

NCT05067283Recruiting

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified ki...

New York, NYPHASE1830 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05719558Recruiting

A Study of ASP1002 in Adults for Treatment of Solid Tumors

The main aims of this study are: * To check the safety of ASP1002 in people with certain solid tumors. * To check if the people can tolerate ASP1002. * To find a suitable dose of ASP1002. This study ...

New York, NYPHASE1798 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT06172478Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma ...

New York, NYPHASE2740 participantsDaiichi Sankyo

View Study Details

NCT06792552Recruiting

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors...

New York, NYPHASE1738 participantsNextCure, Inc.

View Study Details

NCT06179160Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies....

New York, NYPHASE1710 participantsIncyte Corporation

View Study Details

NCT06859762Recruiting

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors...

New York, NYPHASE1630 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT06983743Recruiting

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. E...

New York, NYPHASE1600 participantsErasca, Inc.

View Study Details

NCT05867420Recruiting

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patient...

New York, NYPHASE1594 participantsAskGene Pharma, Inc.

View Study Details

NCT05875168Recruiting

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors....

New York, NYPHASE1590 participantsDaiichi Sankyo

View Study Details

NCT05836324Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors....

New York, NYPHASE1570 participantsIncyte Corporation

View Study Details

NCT05584670Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants ag...

New York, NYPHASE1542 participantsSanofi

View Study Details

NCT06589596Recruiting

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity...

New York, NYPHASE1525 participantsBeOne Medicines

View Study Details

NCT06350539Recruiting

Personalized Models for Cancer Research

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate cancer research ranging from disease mechanisms to personalized medicine approaches that will hel...

New York, NY500 participantsNew York Stem Cell Foundation Research Institute

View Study Details

NCT06051695Recruiting

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell l...

New York, NYPHASE1474 participantsA2 Biotherapeutics Inc.

View Study Details

NCT04855656Recruiting

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced sol...

New York, NYPHASE1464 participantsDebiopharm International SA

View Study Details

NCT04665206Recruiting

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients wit...

New York, NYPHASE1434 participantsVivace Therapeutics, Inc

View Study Details

NCT05932862Recruiting

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of ...

New York, NYPHASE1429 participantsExelixis

View Study Details

NCT04913285Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors....

New York, NYPHASE1400 participantsPierre Fabre Medicament

View Study Details

NCT06625775Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced...

New York, NYPHASE1392 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT06998407Recruiting

Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in pat...

New York, NYPHASE1380 participantsAvenzo Therapeutics, Inc.

View Study Details

NCT03686124Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expres...

New York, NYPHASE1375 participantsImmatics US, Inc.

View Study Details

NCT05669430Recruiting

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care....

New York, NYPHASE1365 participantsGV20 Therapeutics

View Study Details

NCT05824975Recruiting

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembro...

New York, NYPHASE1358 participantsGI Innovation, Inc.

View Study Details

NCT07193511Recruiting

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when admini...

New York, NYPHASE1355 participantsAvenzo Therapeutics, Inc.

View Study Details

NCT06241456Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in pa...

New York, NYPHASE1351 participantsFate Therapeutics

View Study Details

NCT06561685Recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, wit...

New York, NYPHASE1340 participantsEli Lilly and Company

View Study Details

NCT05981703Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced so...

New York, NYPHASE1337 participantsBeOne Medicines

View Study Details

NCT04900818Recruiting

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors....

New York, NYPHASE1330 participantsI-Mab Biopharma US Limited

View Study Details

NCT05720117Recruiting

A Study of PYX-201 in Advanced Solid Tumors

The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (OR...

New York, NYPHASE1330 participantsPyxis Oncology, Inc

View Study Details

NCT04977453Recruiting

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab, lenvatinib or lo...

New York, NYPHASE1317 participantsGI Innovation, Inc.

View Study Details

NCT05434234Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) follo...

New York, NYPHASE1312 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT06952010Recruiting

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s...

New York, NYPHASE1303 participantsExelixis

View Study Details

NCT06752681Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in participants with advanced o...

New York, NYPHASE1300 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT07335497Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) ...

New York, NYPHASE1290 participantsCrescent Biopharma, Inc.

View Study Details

NCT06963281Recruiting

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020....

New York, NYPHASE1285 participantsInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

View Study Details

NCT06167317Recruiting

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced sol...

New York, NYPHASE1278 participantsGilead Sciences

View Study Details

NCT07204340Recruiting

TLN-372 in Advanced KRAS Mutant Solid Tumors

The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with ad...

New York, NYPHASE1270 participantsTreeline Biosciences, Inc.

View Study Details

NCT05768932Recruiting

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or pa...

New York, NYPHASE1260 participantsSillaJen, Inc.

View Study Details

NCT06227377Recruiting

QTX3034 in Patients With KRAS G12D Mutation

Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab....

New York, NYPHASE1250 participantsQuanta Therapeutics

View Study Details

NCT06979596Recruiting

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body...

New York, NYPHASE2250 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06657222Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To ...

New York, NYPHASE1250 participantsTubulis GmbH

View Study Details

NCT04777994Recruiting

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor recep...

New York, NYPHASE1248 participantsCalico Life Sciences LLC

View Study Details

NCT05970497Recruiting

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid ...

New York, NYPHASE1240 participantsKrystal Biotech, Inc.

View Study Details

NCT06682793Recruiting

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head a...

New York, NYPHASE1240 participantsA2 Biotherapeutics Inc.

View Study Details

NCT04942717Recruiting

Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

The purpose of this study is to translate and tailor for Latinx participants a program called Communicating with Oncology Nurses about Values from the Outset (CONVO). In CONVO, routine cancer care for...

New York, NYNA234 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07700160Recruiting

First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential ba...

New York, NYPHASE1230 participantsVelaVigo Bio Inc

View Study Details

NCT05985655Recruiting

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617-001 in participants with advanced solid tumors....

New York, NYPHASE1230 participantsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

View Study Details

NCT05732831Recruiting

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is...

New York, NYPHASE1225 participantsTango Therapeutics, Inc.

View Study Details

NCT06545942Recruiting

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clini...

New York, NYPHASE1220 participantsMOMA Therapeutics

View Study Details

NCT06795412Recruiting

Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced...

New York, NYPHASE1220 participantsPyxis Oncology, Inc

View Study Details

NCT04165772Recruiting

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an eff...

New York, NYPHASE2212 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06597721Recruiting

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as ...

New York, NYPHASE1210 participantsAdcendo ApS

View Study Details

NCT04064359Recruiting

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are norma...

New York, NYPHASE1200 participantsOxford BioTherapeutics Ltd

View Study Details

NCT06695845Recruiting

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor ...

New York, NYPHASE2200 participantsJazz Pharmaceuticals

View Study Details

NCT05422911Recruiting

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have succe...

New York, NYPHASE2192 participantsSun Pharmaceutical Industries Limited

View Study Details

NCT06810544Recruiting

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an op...

New York, NYPHASE1191 participantsTango Therapeutics, Inc.

View Study Details

NCT07374848Recruiting

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer....

New York, NYPHASE1180 participantsZai Lab (Shanghai) Co., Ltd.

View Study Details

NCT07601243Recruiting

Study of GS-2426 in Participants With Advanced Solid Tumors

The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tum...

New York, NYPHASE1174 participantsGilead Sciences

View Study Details

NCT04516447Recruiting

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination ...

New York, NYPHASE1172 participantsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

View Study Details

NCT07197554Recruiting

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies...

New York, NYPHASE1171 participantsSEED Therapeutics, Inc.

View Study Details

NCT06885281Recruiting

A Study of ZL-1310 in Participants With Selected Solid Tumors

A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors...

New York, NYPHASE1166 participantsZai Lab (Shanghai) Co., Ltd.

View Study Details

NCT05270213Recruiting

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endo...

New York, NYPHASE1164 participantsRiboscience, LLC.

View Study Details

NCT07262619Recruiting

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combinat...

New York, NYPHASE1160 participantsEikon Therapeutics

View Study Details

NCT07612176Recruiting

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion p...

New York, NYPHASE1155 participantsNEOK Bio, Inc.

View Study Details

NCT07612189Recruiting

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion po...

New York, NYPHASE1155 participantsNEOK Bio, Inc.

View Study Details

NCT06657144Recruiting

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanc...

New York, NYPHASE1154 participantsCoherus Oncology, Inc.

View Study Details

NCT07436728Recruiting

A Study of TAK-505 in Adults With Solid Tumors

Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in ...

New York, NYPHASE1151 participantsTakeda

View Study Details

NCT06644755Recruiting

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors....

New York, NYPHASE1150 participantsDaiichi Sankyo

View Study Details

NCT07228247Recruiting

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors...

New York, NYPHASE1147 participantsHutchmed

View Study Details

NCT03808337Recruiting

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before partic...

New York, NYPHASE2145 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06014658Recruiting

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

This is a first-in-human (FIH), open label Phase 1/1b / Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biolog...

New York, NYPHASE1130 participantsMBrace Therapeutics

View Study Details

NCT05957536Recruiting

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

This first-in-human (FIH) study, multi-center, open-label, dose escalation and dose expansion Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunoge...

New York, NYPHASE1128 participantsD3 Bio (Wuxi) Co., Ltd

View Study Details

NCT07225088Recruiting

DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer

The purpose of this study is to improve ways of providing mental health support to Spanish-speaking Latino participants who have cancer and experience depression, insomnia, and fatigue. Investigators ...

New York, NYNA125 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06723236Recruiting

A Study of MGC028 in Participants With Advanced Solid Tumors

The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defin...

New York, NYPHASE1124 participantsMacroGenics

View Study Details

NCT06395519Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor acti...

New York, NYPHASE1120 participants858 Therapeutics, Inc.

View Study Details

NCT06425926Recruiting

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary ef...

New York, NYPHASE1117 participantsGeorgiamune Inc

View Study Details

NCT02421380Recruiting

Characterization of Hyperpolarized Pyruvate MRI Reproducibility

The purpose of the study is to test a new approach to see if the test results can be reproduced each time the Magnetic resonance imaging (MRI) is done for an individual patient. The study will explore...

New York, NYNA109 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06975293Recruiting

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalima...

New York, NYPHASE1107 participantsSTORM Therapeutics LTD

View Study Details

NCT07361562Recruiting

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity ...

New York, NYPHASE1100 participantsCogent Biosciences, Inc.

View Study Details

NCT06716138Recruiting

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, a...

New York, NYPHASE196 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT07095868Recruiting

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination...

New York, NYPHASE194 participantsEverest Medicines (Beijing) Co., Ltd.

View Study Details

NCT05103683Recruiting

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer...

New York, NYPHASE190 participantsTORL Biotherapeutics, LLC

View Study Details

NCT07166601Recruiting

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looki...

New York, NYPHASE177 participantsEMD Serono Research & Development Institute, Inc.

View Study Details

NCT06816992Recruiting

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with ...

New York, NYPHASE176 participantsORIC Pharmaceuticals

View Study Details

NCT05886920Recruiting

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with ad...

New York, NYPHASE167 participantsD3 Bio (Wuxi) Co., Ltd

View Study Details

NCT06641908Recruiting

Anti-GD2 ADC M3554 in Advanced Solid Tumors

The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblast...

New York, NYPHASE165 participantsEMD Serono Research & Development Institute, Inc.

View Study Details

NCT06307795Recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in particip...

New York, NYPHASE163 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT05269316Recruiting

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors...

New York, NYPHASE161 participantsImpact Therapeutics, Inc.

View Study Details

NCT06463340Recruiting

Study of SGR-3515 In Participants With Advanced Solid Tumors.

The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors....

New York, NYPHASE152 participantsSchrödinger, Inc.

View Study Details

NCT04890613Recruiting

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid t...

New York, NYPHASE152 participantsSenhwa Biosciences, Inc.

View Study Details

NCT06941272Recruiting

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very y...

New York, NYPHASE150 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07117461Recruiting

A Study of a Distress Screening and Referral Program in People With Recently Diagnosed Cancer

It is recommended that cancer centers screen patients for distress and refer them to mental health services when their distress levels reach a certain level. However, many cancer centers don't have di...

New York, NYNA50 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT04928677Recruiting

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. Th...

New York, NYPHASE150 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05010031Recruiting

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still ...

New York, NYPHASE245 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05487170Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous ...

New York, NYPHASE132 participantsRanok Therapeutics (Hangzhou) Co., Ltd.

View Study Details

NCT07192432Recruiting

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers....

New York, NYPHASE127 participantsVironexis Biotherapeutics Inc.

View Study Details

NCT04997993Recruiting

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

Leflunomide in patients with PTEN-Altered advanced solid tumors or HER2 negative breast cancer. Phase 1A objectives are to determine the safety, tolerability, and the MTD of leflunomide in patients wi...

New York, NYPHASE123 participantsDeborah Doroshow

View Study Details

NCT07638371Recruiting

FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation....

New York, NYPHASE116 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06825715Recruiting

Multilevel Intervention for Precision Oncology

The investigators are rolling out a 3 level intervention designed to improve the use of Precision Oncology at 8 VA medical centers. The 3 components of the intervention are 1: a short educational vide...

New York, NYNA2,653 participantsVA Office of Research and Development

View Study Details

NCT05417594Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participan...

New York, NYPHASE1695 participantsAstraZeneca

View Study Details

NCT07749586Recruiting

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which mean...

New York, NYPHASE1499 participantsArvinas Inc.

View Study Details

NCT07094204Recruiting

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the act...

New York, NYPHASE1404 participantsAstellas Pharma Inc

View Study Details

NCT07408310Recruiting

Trial of Spiritual Care Interventions for Patients With Cancer

This study aims to determine the effects of 2 spiritual care interventions. Spiritual wellness and healthcare service utilization will be measured from a sample of advanced cancer patients recruited f...

New York, NYNA288 participantsWeill Medical College of Cornell University

View Study Details

NCT07195916Recruiting

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies....

New York, NYPHASE1280 participantsIncyte Corporation

View Study Details

NCT07629960Recruiting

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non...

New York, NYPHASE1265 participantsBlueprint Medicines Corporation

View Study Details

NCT07492680Recruiting

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component ...

New York, NYPHASE2260 participantsBristol-Myers Squibb

View Study Details

NCT06060613Recruiting

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors....

New York, NYPHASE1254 participantsObsidian Therapeutics, Inc.

View Study Details

NCT04752826Recruiting

BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed...

New York, NYPHASE1250 participantsBioInvent International AB

View Study Details

NCT05398484Recruiting

Psilocybin Therapy in Advanced Cancer

The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existent...

New York, NYPHASE2200 participantsNYU Langone Health

View Study Details

NCT05902988Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers....

New York, NYPHASE1200 participantsVolastra Therapeutics, Inc.

View Study Details

NCT07196644Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab ad...

New York, NYPHASE2100 participantsAbbVie

View Study Details

NCT06234098Recruiting

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-196...

New York, NYPHASE1100 participantsAlyssum Therapeutics

View Study Details

NCT05004116Recruiting

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

This study will test the safety of the study drug, repotrectinib, in combination with chemotherapy (irinotecan and temozolomide) in children and young adults who have advanced or metastatic solid tumo...

New York, NYPHASE177 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07408258Recruiting

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors,...

New York, NYPHASE120 participantsOncoC4, Inc.

View Study Details

About Advanced Solid Tumors Clinical Trials in New York

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 116 advanced solid tumors clinical trials recruiting participants in New York, NY. These studies are seeking a combined 36,765 participants. Research is being sponsored by Memorial Sloan Kettering Cancer Center, Alliance Foundation Trials, LLC., Merck Sharp & Dohme LLC and 83 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in New York — FAQ

Are there advanced solid tumors clinical trials in New York?

Yes, there are 116 advanced solid tumors clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New York?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.

Are clinical trials in New York free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 116 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated October 16, 2026 from ClinicalTrials.gov